Jasper Therapeutics Inc
NASDAQ:JSPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zhejiang HangKe Technology Incorporated Co
SSE:688006
|
CN |
|
Bosideng International Holdings Ltd
OTC:BSDGY
|
HK |
|
G
|
Guizhou Qianyuan Power Co Ltd
SZSE:002039
|
CN |
|
Fast Finance 24 Holding AG
XETRA:FF24
|
DE |
|
Zambal Spain Socimi SA
MAD:YZBL
|
ES |
|
A
|
Apple Flavor & Fragrance Group Co Ltd
SSE:603020
|
CN |
|
I
|
Interglobe Aviation Ltd
BSE:539448
|
IN |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
26.1m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
371.7B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
174.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.8B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.9B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.6B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
66.6B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Jasper Therapeutics Inc
Glance View
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 25 full-time employees. The company went IPO on 2019-11-20. The firm has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. The company is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The firm also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases.JSP191 clear hematopoietic stem cells from the bone marrow prior to transplant.
